维布妥昔单抗治疗CD30阳性淋巴瘤临床应用指导原则中国专家共识(2022年版)

Chinese expert consensus on principles for clinical practice of brentuximab vedotin in CD30-positive lymphoma(2022 version)

维布妥昔单抗(BV)是一种抗体-药物偶联物,于2020年5月在我国获批上市,目前已经被批准用于成年CD30阳性淋巴瘤患者,包括复发难治经典型霍奇金淋巴瘤、复发难治系统性间变性大细胞淋巴瘤、既往接受过系统性治疗的原发性皮肤间变性大细胞淋巴瘤或蕈样霉菌病。目前BV在临床实践中的应用数据尚待完善。为了进一步规范BV在CD30阳性淋巴瘤患者中的临床应用,专家组成员结合BV应用现状及已经公布的BV相关研究数据,制定了该临床应用指导原则,供临床医生参考。

As an antibody-drug conjugate(ADC),brentuximab vedotin(BV)has been approved in treatment of adult CD30-positive lymphoma including relapsed/refractory classic Hodgkin lymphoma,relapsed/refractory systemtic anaplastic large cell lymphoma,and systematically treated primary cutaneous anaplastic large cell lymphoma or mycosis fungoides.BV as a novel ADC was launched in May 2020,however,its data in clinical practice remains limited.To standardize the clinical practice of BV in CD30-positive lymphoma patients,the Chinese experts work out this clinical guidance by combining the current clinical application of BV and published data of BV to provide references for clinical physicians.